Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines

S N ROGERS1,2, C SEMPLE3, M BABB4, G HUMPHRIS5

1Evidence-Based Practice Research Centre, Faculty of Health, Edge Hill University, Ormskirk, 2Regional Maxillofacial Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, 3Department of Head and Neck Cancer, Cancer Services, South Eastern Health & Social Care Trust, Belfast, 4NCRI Head and Neck Clinical Studies Group, NCIN Head and Neck Site Specific Clinical Reference Group, B16 – Complex Head and Neck Clinical Reference Group, Chesterfield, Derbyshire, and 5Medical School, University of St Andrews, St Andrews, UK

Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. It identifies the current evidence base and role of health-related quality of life assessment for this group of patients.

Recommendations
• Health-related quality of life is integral to treatment planning, refining treatment protocols, and more personalised follow-up support. (G)
• Health-related quality of life and patient concerns should be regularly assessed during patient care. (G)
• Health-related quality of life assessment and patient concerns on an individual patient basis can be helpful to trigger multi-professional support and interventions. (G)

The evaluation of the quality of life (QoL) in patients with head and neck cancer is integral to optimal patient care.1 Survival is usually the initial primary concern of patients and the focus is on treatments that offer the best chance of cure as a priority. However, after treatment there tends to be a shift towards QoL and living with the consequences of head and neck cancer treatment (survivorship).

What is quality of life?
Quality of life is a multifaceted construct comprising many different aspects leading to numerous definitions. The World Health Organization defines quality of life as an “individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns”.2 Quality of life comprises a person’s physical health and functioning, psychological state, level of independence, social relationships, occupation and finance, and personal beliefs. There is a complex relationship between factors such as the characteristics of the individual with respect to symptoms, personality, motivation, value preferences and the characteristics of the environment such as psychological, social and economic support.2 The term ‘health-related quality of life’ (HRQoL) is more disease specific and allows the healthcare professions to focus upon the assessment of the impact of the disease and its treatment on the physical, psychological and social aspects.3

Why should we measure quality of life?
Health-related quality of life evaluation gives an indication of how the patient perceives the impact of their cancer and its treatment. This information can be used to give the patient and their family an indication of ‘what will I be like’.1 This patient reported outcome allows the health professional an opportunity to reflect on the patient’s reaction. Individual patient-rated outcomes can often differ quite markedly from clinician-rated scores. Health-related quality of life measurement has a role in evaluating treatment outcomes, helping to define treatment protocols, as primary or secondary outcome(s) of clinical trials, providing additional information to assist in individual decision-making processes, to support the identification of poor outcomes, so that intervention and support can be considered.4 Checklists such as the
Patients Concerns Inventory help patients express unmet concerns and can be used as part of holistic needs assessment. A better understanding of patients’ perception helps facilitate improvements in aftercare and serves to drive clinically relevant outcomes research. Also patient-reported outcomes should be part of national outcome datasets.

It is appreciated that there are many potential difficulties in assessing HRQoL in clinical practice. Perhaps the biggest challenges are: (i) the burden of administration and processing of the questionnaires; (ii) the reality that patients tend to adapt over time, so that expected differences between treatments might not be as significant as anticipated; (iii) that HRQoL data are weighted to survivors; and (iv) that there is little evidence of agreed standards of analysis and reporting. Another barrier is the lack of evidence as to when HRQoL should have a major role on treatment decisions, or an important role simply as an additional factor, or perhaps where it has relatively little value. Hence, healthcare professionals can unrealistically rely too much on the value of HRQoL in certain clinical situations and this can lead to frustration and a perceived lack of benefit in the HRQoL process.

**How should it be measured?**

The commonest way to measure HRQoL is by patient self-completed questionnaire (quantitative) although other methods include open and semi-structured interview (qualitative). There is no gold standard questionnaire and each has its own unique features and merits. All questionnaires are inherently limited by the range of issues addressed, the wording used, and the scoring systems. The choice of questionnaire depends on the reason for using it, e.g. research, audit, integrated into routine clinical practice or to assist in the evaluation of a specific functional outcome.

Questionnaires can be used either cross-sectionally or longitudinally. Longitudinal data from pre-treatment has the distinct advantage of allowing the measurement of change and also recording HRQoL during the different phases of treatment. It is a logistical challenge to ensure patients self-complete questionnaires before treatment and at regular intervals subsequently. Cross-sectional evaluation is simpler to conduct and easier to achieve larger patient numbers when stratifying for patient characteristics. Questionnaires can be divided into four main categories: (i) those asking on a range of broad issues not specific to cancer; (ii) those addressing issues common to all cancers; (iii) questionnaires with items specific to head and neck cancer; and (iv) those questionnaires that focus in detail on a particular aspect of head and neck function.

With changes in treatments e.g. epidermal growth factor receptor inhibitors as part of chemotherapy, so existing HRQoL questionnaires might need to be modified to include additional side effects and functional deficits. As the relationship between unmet need and HRQoL becomes more clearly understood, further consideration needs to be given as to how, within the financial constraints of cancer care, questionnaires can be more easily integrated into routine practice. Advances in technology will assist in the collection and inclusion of patient-reported outcomes. The almost ubiquitous ownership of mobile phones allows developers in partnership with clinical researchers to construct ‘Apps’ that can send alerts to patients for HRQoL updates on certain features. This is an exciting area that is in its infancy but holds great promise to enable a more comprehensive, flexible and frequent opportunity to explore, study and intervene in patient HRQoL.

**What are the key issues?**

There are a considerable range of issues that impact on the HRQoL outcomes following head and neck cancer. This section makes only very brief comment on the type of issues involved (listed in alphabetical order). There are several review articles that give additional information. At the present time there tends to be a lack of long-term outcomes reported in the literature. Also newer treatment strategies are under reported given the time necessary to get adequate HRQoL information.

- **Carer:** there is a need to promote positive carer support; carers can underestimate the HRQoL outcome
- **Comorbidity:** patient perception of disability, rather than the extent and severity of disease is of major influence in head and neck HRQoL
- **Coping:** social support seeking is beneficial whilst avoidance is bad
- **Dental status:** eating – social interaction and is linked to coping
- **Disfigurement:** appearance, body image, not only an issue in surgical patients
- **Emotion:** anxiety is high pre-treatment; mood disturbance and/or depression is treatable
- **Family and children:** the impact of cancer affects family and community
- **Fatigue:** common in the first year post-treatment; poor sleep; low energy
- **Fear of recurrence:** unpredictable by clinical characteristics; does not lessen over time; and high levels predict higher consumption of formal healthcare.
- **Financial and work:** employment; benefits; cost of treatment and follow-up; and retirement
- **Function:** pre-existing comorbidities; problems of combination treatment modalities – impact on recreation, hobbies, interests. In general, the less the consequence of the cancer and its treatment in terms of social function the better the HRQoL outcomes
- **Fungating wounds:** difficulties in palliation in head and neck; relatively few published papers...
Examples of how HRQoL might change practice

Health-related quality of life is a factor that is weighed against treatment burden and toxicity, and also any survival benefit between treatments. In the three common head and neck cancer sites, HRQoL might be a driver for evolving strategies alongside other drivers such as survival, function and healthcare cost. Examples are described below.

Oropharynx

1. Early stage disease: There is an argument for transoral excision for early oropharynx lesions with selective neck dissection. This avoids the need for free tissue transfer and access procedures such as lip split mandibulotomy. 
   *Drivers for change:* Health-related quality of life, survival, function, cost to National Health Service (reduced length of stay).

2. Advanced stage disease: Chemoradiotherapy is often advocated for larger oropharyngeal primaries if laser resection is not possible. The long-term outcomes remain unclear as does the success of salvage surgery and its impact on HRQoL. The benefit of salvage surgery and the impact on HRQoL is currently uncertain. Transoral surgery is problematic due to the high-risk of local necrosis, non-healing and catastrophic bleeding. The use of free flap reconstruction in the post-chemoradiotherapy failures, is often associated with poor functional outcomes, poor HRQoL and limited cure rates.
   *Drivers for change:* Health-related quality of life; function; healthcare cost.

3. Human papilloma virus (HPV) testing: It is conceivable that it is possible to de-escalate treatment in some HPV positive patients. Similar survival outcomes may be achieved by the use of cetuximab and radiotherapy rather than platinum-based chemoradiotherapy.
   *Drivers for change:* Health-related quality of life.

Larynx

1. Early stage disease: Laser excision rather than primary radiotherapy for suitable lesions.
   *Drivers for change:* Patient choice based on equivalent HRQoL and survival.

2. Advanced stage disease: There is debate about chemoradiotherapy or laryngectomy. Following chemoradiotherapy the success and impact of laryngectomy for salvage remains to be fully determined.
   *Drivers for change:* Health-related quality of life, survival.

Oral cavity

1. Early stage disease: There is a rationale towards primary surgery without free tissue reconstruction accepting close margins with low risk of local recurrence.
   *Drivers for change:* Health-related quality of life, survival, function, cost of overall treatment.

2. Advanced stage disease: Primary surgery with free tissue reconstruction as required. However, there is discussion around the benefit of adjuvant radiotherapy.
   *Drivers for change:* Health-related quality of life, survival.

Conclusion

The place of HRQoL assessment in head and neck cancer practice has become more defined in the last decade. It has had a major role in helping to shape treatment strategies and patient support. More evidence is yet to emerge to improve guidance as to how to use HRQoL at an individual patient level and also reflect the trade off between marginal survival improvements and increased treatment burden and poorer HRQoL. Advances in information technology will make it
Directions for the future

1. Holistic assessment integrated into clinical practice and patient reported outcomes reported in national datasets.

2. Survivorship issues addressed through interventions and empowering patients to develop skills and confidence for self-management.

3. Evidence base related to interventions, e.g. AFTER intervention for fear of recurrence.

4. A better understanding of late effects of treatment.

5. Partnership and marital issues are no doubt of significant importance, as well as grandparents and children (family). Interventions need to include couple therapy and family therapy and practitioners need to be trained in these approaches as well as individual counselling etc.

6. Wider use of information technology to allow HRQoL and patient concerns to be more readily available in clinics and across the multi-professional team.

References

1. Rogers SN, Hogg ES, Cheung WK, Lai JK, Jassal P, Lowe D et al. ‘What will I be like’ after my diagnosis of head and neck cancer? Eur Arch Otorhinolaryngol 2015;272:2463–72

2. Saxena S, Orley J. Quality of life assessment: the world health organization perspective. Eur Psychiatry 1997;12:263–6

3. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995;273:59–65

4. Rogers SN. Oral Cancer Management: Pitfalls and Solutions. Article: Rogers SN Quality of life of head and neck cancer patients. Has treatment planning altered? Oral Oncol 2009;45:435–9

5. Rogers SN, El-Sheikh J, Lowe D. The development of a Patients Concerns Inventory (PCI) to help reveal patients concerns in the head and neck clinic. Oral Oncol 2009;45:555–61

6. Rogers SN. Quality of life perspectives in patients with oral cancer. Oral Oncol 2010;46:445–7

7. Rogers SN, Kanatas A. Assessment of outcomes in quality of life for head and neck cancer patients. In: Kazi R, Rhys-Evans P, Harrington KJ, eds. Issues in Head and Neck Cancer. Dwivedi RC. Byword Books Private Limited, Delhi 2012; 117–25, ISBN 978-81-8193-076-5

8. Seyed SI, Eluyech B, Rhys-Evans U, Syrigos KN, Nutting CM, Harrington KJ et al. Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev 2009;35:397–402

9. Laraway DC, Rogers SN. A structured review of journal articles reporting outcomes using the University of Washington Quality of Life Scale. Br J Oral Maxillofac Surg 2012;50:122–31

10. Rogers SN, Ahad SA, Murphy AP. A structured review and theme analysis of papers published on ‘quality of life’ in head and neck Cancer: 2000 to 2005. Oral Oncol 2007;43:843–68

11. Aaronson NK, Bullinger M, Ahmedzai S. A Modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 1988;111:231

12. Kanatas AN, Rogers SN. A guide to the questionnaires used in the measurement of health-related quality of life in head and neck oncology. Tumori 2008;94:724–31

13. Kanatas AN, Mehanna H, Lowe D, Rogers SN. A second national survey of health-related quality of life questionnaires in head and neck oncology. Ann R Coll Surg Engl 2009;91:420–5

14. Kanatas AN, Rogers SN. A national survey of health-related quality of life questionnaires in head and neck oncology. Ann R Coll Surg Engl 2004;86:6–10

15. Rogers SN, Lowe D. Screening for dysfunction to promote MDT intervention using the University of Washington Quality of Life questionnaire (UW-QOL). Arch Otolaryngol Head Neck Surg 2009;135:369–75

16. Ojo B, Genden EM, Teng MS, Milbury K, Misukiewicz KJ, Badr H. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol 2012;48:923–37

17. Rogers SN. Quality of life. Chapter 10. Stell and Maran’s Textbook of Head and Neck Surgery and Oncology, 5th edn, Eds Watkinson J and Gilbert RW. Taylor and Francis Group LLC, Boca Raton, FL, 2012: 182–94. ISBN 978-0-340-92916-2

Address for correspondence:
Simon N. Rogers, Evidence-Based Practice Research Centre, Faculty of Health, Edge Hill University, Ormskirk and Regional Maxillofacial Unit, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK
E-mail: snrogers.aintytree@gmail.com